Expertise in
4
conditions

Dr. Dharamvir Jain

Oncology
Robley Rex Department Of Veterans Affairs Medical Center
800 Zorn Ave, 
Louisville, KY 
Accepting New Patients
Expertise in
4
conditions
Robley Rex Department Of Veterans Affairs Medical Center
800 Zorn Ave, 
Louisville, KY 

Overview

Dharamvir Jain is an Oncologist practicing medicine in Louisville, Kentucky.

Dr. Jain is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Inflammatory Breast Cancer, Breast Cancer, and Angiosarcoma.

He is actively involved in clinical research, co-authoring 23 peer reviewed articles and participating in 7 clinical trials. Dr. Jain is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in KY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Robley Rex Department of Veterans Affairs Medical Center
800 Zorn Ave, Louisville, KY 40206

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
Extended Interval Port Flushes: A Phase II Clinical Trial
Extended Interval Port Flushes: A Phase II Clinical Trial
Enrollment Status: Completed
Publish Date: July 19, 2021
Intervention Type: Other
Study Phase: Phase 2
Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)
Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)
Enrollment Status: Completed
Publish Date: February 19, 2018
Intervention Type: Other, Procedure, Genetic, Biological, Drug
View 6 Less Clinical Trials

23 Total Publications

Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer Patients.
Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer Patients.
Journal: Anticancer research
Published: December 29, 2024
Similar Doctors
Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Uofl Health-Brown Cancer Center

529 S Jackson St, 
Louisville, KY 
 (2.9 miles away)
502-562-4673
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jason Chesney is an Oncologist practicing medicine in Louisville, Kentucky. Dr. Chesney is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Melanoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma. Dr. Chesney is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

Norton Cancer Institute - Downtown

676 South Floyd Street, 
Louisville, KY 
 (3.3 miles away)
502-629-2500
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Hamm is an Oncologist practicing medicine in Louisville, Kentucky. Dr. Hamm is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Pancreatic Cancer, and Pleuropulmonary Blastoma. Dr. Hamm is board certified in American Board Of Internal Medicine, Medical Oncology - 1989 and American Board Of Internal Medicine, Internal Medicine - 1985. Dr. Hamm is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Norton Cancer Institute Brownsboro

4955 Norton Healthcare Blvd, 
Louisville, KY 
 (7.3 miles away)
502-394-6350
Languages Spoken:
English, Italian
See accepted insurances
Accepting New Patients

Renato La Rocca is an Oncologist practicing medicine in Louisville, Kentucky. Dr. La Rocca is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Embryonal Tumor with Multilayered Rosettes, Atypical Teratoid Rhabdoid Tumor (ATRT), and Neuroepithelioma. Dr. La Rocca is currently accepting new patients.

Frequently Asked Questions about Dr. Dharamvir Jain

How do I make an appointment with Dr. Dharamvir Jain?

You can book an appointment with Dr. Dharamvir Jain by calling their office at 502-287-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Dharamvir Jain a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Dharamvir Jain is classified as an Distinguished expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Dharamvir Jain specialize in?

While Dr. Dharamvir Jain is a Oncology, they have specific expertise in Paget Disease of the Breast, Inflammatory Breast Cancer, and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Dharamvir Jain participate in research or clinical trials?

Yes. Dr. Dharamvir Jain has published 23 articles and abstracts on conditions like Paget Disease of the Breast. You can view a list of Dr. Dharamvir Jain's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Dharamvir Jain accept my insurance?

Dr. Dharamvir Jain accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 502-287-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile